Article Text

Download PDFPDF
Palliative care need screening and specialised referrals fell during the COVID-19 pandemic: a nationwide register-based study
  1. Maiken Bang Bang Hansen1,2,
  2. Mogens Groenvold1,3,
  3. Mathilde Adsersen1,
  4. Henry Jensen4,
  5. Else Helene Ibfelt2,
  6. Morten Aagaard Petersen1,
  7. Mette Asbjørn Neergaard5,6,
  8. Henrik Møller2 and
  9. Tina Bech Olesen4
  1. 1The Research Unit, Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark
  2. 2Department of Cancer and Cancer Screening, The Danish Clinical Quality Program – National Clinical Registries (RKKP), Copenhagen, Denmark
  3. 3Department of Public Health, Copenhagen University, Copehagen, Denmark
  4. 4Department of Resources and Innovation, The Danish Clinical Quality Program – National Clinical Registries (RKKP), Copenhagen, Denmark
  5. 5Palliative Care Unit, Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
  6. 6Department of Clinical Medicine, Aarhus University, Aarhus, Midtjylland, Denmark
  1. Correspondence to Mrs Maiken Bang Bang Hansen, The Research Unit, Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark; maiken.bang.hansen{at}regionh.dk

Abstract

Objectives Few studies have examined whether access to, and quality of, specialised palliative care changed during the COVID-19 pandemic. This study investigated changes in access to and quality of specialised palliative care during the pandemic in Denmark compared to previously.

Methods An observational study using data from the Danish Palliative Care Database combined with other nationwide registries was conducted, including 69 696 patients referred to palliative care services in Denmark from 2018 to 2022. Study outcomes included number of referrals and admissions to palliative care, and the proportions of patients fulfilling four palliative care quality indicators. The indicators assessed admissions among referred, waiting time from referral to admission, symptom screening using the European Organisation for Research and Treatment of Cancer Quality of Life Questionaire-Core-15-Palliative Care (EORTC QLQ-C15-PAL) questionnaire at admission, and discussion at multidisciplinary conference. Logistic regression analysed whether the probability of fulfilling each indicator differed between the pandemic period and pre-pandemic, while adjusting for possible confounders.

Result Number of referrals and admissions to specialised palliative care were lower during the pandemic. The odds for being admitted within 10 days of referral was higher during the pandemic (OR: 1.38; 95% CI: 1.32 to 1.45) whereas the odds for answering the EORTC questionnaire (0.88; 95% CI: 0.85 to 0.92) and for being discussed at multidisciplinary conference (0.93; 95% CI: 0.89 to 0.97) were lower compared with pre-pandemic.

Conclusions Fewer patients were referred to specialised palliative care during the pandemic, and fewer were screened for palliative care needs. In future pandemics or similar scenarios, it is important to pay special attention to referral rates and to maintain the same high level of specialised palliative care.

  • COVID-19
  • Hospice care
  • Hospital care
  • Quality of life
  • Cancer
  • Chronic conditions

Data availability statement

Data may be obtained from a third party and are not publicly available.

This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data may be obtained from a third party and are not publicly available.

View Full Text

Footnotes

  • Contributors All authors made substantial contributions to the design, analysis of data, critical revision and approved the publication, participating sufficiently to take responsibility for the content of this article. MBH is the guarantor of this article and responsible for the overall content of the article.

  • Funding The study was funded by the Danish Cancer Society Scientific Committee (grant number R321-A17417), and the Danish regions.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.